Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elutia ( (ELUT) ) just unveiled an announcement.
Elutia has resolved prior Nasdaq compliance issues that arose in late 2025, when its Class A common stock traded below the $1.00 minimum bid price for 30 consecutive business days and its market value of listed securities fell under the $35 million threshold, also failing to meet alternative equity and income standards. On February 5, 2026, Nasdaq notified Elutia that it had regained compliance with the market value requirement, and on March 2, 2026, the exchange confirmed the company had also restored compliance with the minimum bid price rule, ensuring its shares remain listed on the Nasdaq Capital Market under the symbol ELUT.
In a March 4, 2026 press release, Elutia announced that Nasdaq now considers both matters closed and that the company is in full compliance with all continued listing requirements. Management framed the recovery in share price and market value as a sign of renewed investor confidence in its drug-eluting biomatrix technology and market prospects, a development that stabilizes trading status for shareholders and supports Elutia’s visibility and credibility in the public markets.
The most recent analyst rating on (ELUT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Elutia stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
The score is held down primarily by weak financial performance (losses, negative equity, and negative cash flows). Technicals are modestly supportive with improving short-term momentum, but the longer-term trend remains down. The earnings call adds a positive offset due to the cash-generating divestiture and margin/expense improvements, while Nasdaq noncompliance events add meaningful risk.
To see Spark’s full report on ELUT stock, click here.
More about Elutia
Elutia Inc., based in Gaithersburg, Md., is a medical technology company specializing in drug-eluting biomatrix products designed to improve compatibility between implantable medical devices and patients. The company targets the growing population requiring implantable technologies, positioning its platform to address a large market opportunity in advanced biomaterials and device integration.
Average Trading Volume: 367,489
Technical Sentiment Signal: Hold
Current Market Cap: $52.1M
For detailed information about ELUT stock, go to TipRanks’ Stock Analysis page.